H Lundbeck A/S
CSE:HLUN A
H Lundbeck A/S
Net Change in Cash
H Lundbeck A/S
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
H Lundbeck A/S
CSE:HLUN A
|
Net Change in Cash
-kr346m
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Novo Nordisk A/S
CSE:NOVO B
|
Net Change in Cash
-kr34.4B
|
CAGR 3-Years
-186%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ALK-Abello A/S
CSE:ALK B
|
Net Change in Cash
kr226m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Stenocare A/S
CSE:STENO
|
Net Change in Cash
-kr8.1m
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
H Lundbeck A/S
Glance View
Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.
See Also
What is H Lundbeck A/S's Net Change in Cash?
Net Change in Cash
-346m
DKK
Based on the financial report for Dec 31, 2024, H Lundbeck A/S's Net Change in Cash amounts to -346m DKK.
What is H Lundbeck A/S's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
41%
The average annual Net Change in Cash growth rates for H Lundbeck A/S have been 41% over the past three years .
You don't have any saved screeners yet